At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.